Cardiac hypertrophy is the heart's compensatory response to a variety of extrinsic and intrinsic stimuli. Cardiac hypertrophy is believed to have a compensatory function by diminishing wall stress. Yet, paradoxically, ventricular hypertrophy is associated with a significant increase in the risk of heart failure and malignant arrhythmia. Inhibition of the nuclear factor, NF-?B, has recently been investigated as one of the possible therapeutic approaches to the treatment of cardiac hypertrophy and the results, and clinical significance promise to be vast. We surmised that the use of soluble inhibitors of NF-?B would present an attractive therapeutic means to treat cardiac hypertrophy. On the other hand, NF-?B can be both anti- and pro-apoptotic in certain conditions. Therefore, the beneficial effects of NF-?B inhibitors in cardiac hypertrophy remain to be systematically investigated. Motivated by the uncertainties, and the therapeutic potential of the inhibitors of this nuclear factor, we have obtained surprising yet, exciting data which demonstrate the beneficial effects of several novel potent soluble epoxide hydrolase (sEH) inhibitors in cardiac hypertrophy. sEH catalizes the conversion of epoxyeicosatrienoic acids (EETs) to form the corresponding dihydroxyeicosatrienoic acids (DHETs). EETs are products of cytochrome P450 epoxygenases that have vasodilatory properties similar to that of endothelium-derived hyperpolarizing factor. In addition, EETs inhibit the activation of NF-?B-mediated gene transcription. Specifically, we have shown that there is an almost complete resolution of cardiac hypertrophy by sEH inhibitors independent of the antihypertensive effects. We were able to demonstrate in our preliminary findings that these compounds potently block the NF-?B activation in cardiac myocytes. Moreover, our study shows a beneficial effect of the compounds in the prevention of cardiac arrhythmias which occur in association with cardiac hypertrophy. Inspired by these initial observations, we reason that these compounds can be exploited to be used as a tool to systematically probe the possible beneficial effects of sEH inhibition in the short- and long-term treatment of cardiac hypertrophy as well as to study the mechanisms and involvement of NF-?B signaling pathway in cardiac hypertrophy. Thus, the central goal of the proposal is to use sEH inhibitors to directly test the novel concept that enhancement of endogenous EETs can be used as a mean to prevent and reverse cardiac hypertrophy and prevent the occurrence of cardiac arrhythmias via inhibition of NF-?B activation.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL085727-03
Application #
7763877
Study Section
Special Emphasis Panel (ZRG1-CVS-F (02))
Program Officer
Lathrop, David A
Project Start
2008-02-01
Project End
2012-01-31
Budget Start
2010-02-01
Budget End
2011-01-31
Support Year
3
Fiscal Year
2010
Total Cost
$380,000
Indirect Cost
Name
University of California Davis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Gluck, Jessica M; Herren, Anthony W; Yechikov, Sergey et al. (2017) Biochemical and biomechanical properties of the pacemaking sinoatrial node extracellular matrix are distinct from contractile left ventricular matrix. PLoS One 12:e0185125
Sirish, Padmini; Ledford, Hannah A; Timofeyev, Valeriy et al. (2017) Action Potential Shortening and Impairment of Cardiac Function by Ablation of Slc26a6. Circ Arrhythm Electrophysiol 10:
López, Javier E; Sharma, Janhavi; Avila, Jorge et al. (2017) Novel large-particle FACS purification of adult ventricular myocytes reveals accumulation of myosin and actin disproportionate to cell size and proteome in normal post-weaning development. J Mol Cell Cardiol 111:114-122
Zhang, Zheng; Ledford, Hannah A; Park, Seojin et al. (2017) Distinct subcellular mechanisms for the enhancement of the surface membrane expression of SK2 channel by its interacting proteins, ?-actinin2 and filamin A. J Physiol 595:2271-2284
Frederich, Bert J; Timofeyev, Valeriy; Thai, Phung N et al. (2017) Electrotaxis of cardiac progenitor cells, cardiac fibroblasts, and induced pluripotent stem cell-derived cardiac progenitor cells requires serum and is directed via PI3'K pathways. Heart Rhythm 14:1685-1692
Sirish, Padmini; Li, Ning; Timofeyev, Valeriy et al. (2016) Molecular Mechanisms and New Treatment Paradigm for Atrial Fibrillation. Circ Arrhythm Electrophysiol 9:
Awasthi, Samir; Izu, Leighton T; Mao, Ziliang et al. (2016) Multimodal SHG-2PF Imaging of Microdomain Ca2+-Contraction Coupling in Live Cardiac Myocytes. Circ Res 118:e19-28
Yechikov, Sergey; Copaciu, Raul; Gluck, Jessica M et al. (2016) Same-Single-Cell Analysis of Pacemaker-Specific Markers in Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Subtypes Classified by Electrophysiology. Stem Cells 34:2670-2680
Sihn, Choong-Ryoul; Kim, Hyo Jeong; Woltz, Ryan L et al. (2016) Mechanisms of Calmodulin Regulation of Different Isoforms of Kv7.4 K+ Channels. J Biol Chem 291:2499-509
Wang, Wenying; Flores, Maria Cristina Perez; Sihn, Choong-Ryoul et al. (2015) Identification of a key residue in Kv7.1 potassium channel essential for sensing external potassium ions. J Gen Physiol 145:201-12

Showing the most recent 10 out of 63 publications